Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your organization on the next page. You will be redirected to verify your credentials.

OpenAthens/Shibboleth

Original Paper

Characterization of the Integrin αvβ3 in Arteriovenous Malformations and Cavernous Malformations

Lim M.a · Haddix T.c · Harsh G.R.a · Vogel H.c · Steinberg G.K.a · Guccione S.b

Author affiliations

Departments of aNeurosurgery, bRadiology and cNeuropathology, Stanford University, Stanford, Calif., USA

Related Articles for ""

Cerebrovasc Dis 2005;20:23–27

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 18, 2005
Accepted: March 22, 2005
Published online: July 08, 2005
Issue release date: July 2005

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Abstract

Background: Alpha V beta 3 (αvβ3) is an integrin specifically expressed on the endothelial cells of central nervous system (CNS) neoplasms. However, no data exist on the expression of αvβ3 in vascular malformations of the CNS. In this study, we investigate the expression of αvβ3 in arteriovenous malformations (AVMs) and cavernous malformations (CMs). Method: Frozen samples of AVMs from 12 patients and CMs from 5 patients were obtained intraoperatively. Once the final pathology had been confirmed, immunohistochemistry was performed using an antibody to the integrin αvβ3. The αvβ3 expression pattern was graded according to the percentage of positively staining vessels. Results: Ten of 12 AVMs demonstrated αvβ3 immunopositivity. Six of these 10 AVMs had moderate or strong staining. Most notably, 5 of the 6 moderate or strongly staining AVMs came from patients 22 years of age or younger. Four of these 6 AVMs had previously been embolized. None of the cavernous malformations demonstrated αvβ3 immunopositivity. Discussion: αvβ3 may contribute to the formation of AVMs in younger patients. αvβ3 may also provide a potential therapeutic target. The lack of αvβ3 expression in cavernous malformations, despite their high vascular densities, suggests that the pathophysiology of their formation differs from that of AVMs.

© 2005 S. Karger AG, Basel


References

  1. Shenkar R, Elliott JP, Diener K, Gault J, Hu LJ, Cohrs RJ, Phang T, Hunter L, Breeze RE, Awad IA: Differential gene expression in human cerebrovascular malformations. Neurosurgery 2003;52:465–477.
  2. Baev NI, Awad IA: Endothelial cell culture from human cerebral cavernous malformations. Stroke 1998;29:2426–2434.
  3. Kontos CD, Annex BH: Angiogenesis. Curr Atheroscler Rep 1999;1:165–171.
  4. Ondrick K, Samojla BG: Angiogenesis. Clin Podiatr Med Surg 1992;9:185–202.
  5. Swerlick RA: Angiogenesis. J Dermatol 1995;22:845–852.
  6. Hartmann A, Mast H, Mohr JP: Morbidity of intracranial hemorrhage in patients with cerebral arteriovenous malformation. Stroke 1998;29:931–934.
  7. Hofmeister C, Stapf C, Hartmann A: Demographic, morphological, and clinical characteristics of 1,289 patients with brain arteriovenous malformation. Stroke 2000;31:1307–1310.
  8. Mast H, Young WL, Koennecke HC: Risk of spontaneous haemorrhage after diagnosis of cerebral arteriovenous malformation. Lancet 1997;350:1065–1068.
  9. Robinson JR Jr, Awad IA, Little JR: Natural history of the cavernous angioma. J Neurosurg 1991;75:709–714.
  10. Curling OD Jr, Kelly DL Jr, Elster AD, et al: An analysis of the natural history of cavernous angiomas. J Neurosurg 1991;75:702–708.
    External Resources
  11. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.
  12. Kleihues P BP, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK: Pathology andGenetics of Tumours of the Nervous System. Lyon, IARC Press, 2000.
  13. Pardanaud L, Yassine F, Dieterlen-Lievre F: Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development 1989;105:473–485.
  14. Robertson PL, Du Bois M, Bowman PD, et al: Angiogenesis in developing rat brain: An in vivo and in vitro study. Brain Res 1985;355:219–223.
  15. Colognato H, Yurchenco PD: Form and function: The laminin family of heterotrimers. Dev Dyn 2000;218:213–234.
  16. Friedlander M, Brooks PC, Shaffer RW, et al: Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270:1500–1502.
  17. Gladson CL, Cheresh DA: Glioblastoma expression of vitronectin and the alpha v beta 3 integrin: Adhesion mechanism for transformed glial cells. J Clin Invest 1991;88:1924–1932.
  18. Bello L, Francolini M, Marthyn P, et al: Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery. 2001;49:380–389.
  19. Folkman J, D’Amore PA: Blood vessel formation: What is its molecular basis? Cell 1996;87:1153–1155.
  20. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11–25.
  21. Hood JD, Bednarski M, Frausto R, et al: Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404–2407.
  22. Clatterbuck RE, Eberhart CG, Crain BJ, Rigamonti D: Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J Neurol Neurosurg Psychiatry 2001;71:188–192.
  23. Wong JH, Awad IA, Kim JH: Ultrastructural pathological features of cerebrovascular malformations. Neurosurgery 2000;46:1454–1459.
  24. Brooks PC: Role of integrins in angiogenesis. Eur J Cancer 1996;32A:2423–2429.
  25. Eliceiri BP, Cheresh DA: Adhesion events in angiogenesis. Curr Opin Cell Biol 2001;13:563–568.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 18, 2005
Accepted: March 22, 2005
Published online: July 08, 2005
Issue release date: July 2005

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.